Alere™ q HIV-1/2 Detect
A child born today to an HIV positive mother faces great challenges in reaching their first birthday. HIV diagnosis in infants is difficult as common antibody tests are ineffective.
According to a recent joint WHO/UNAIDS/UNICEF report, an estimated 72 percent of children born to HIV-positive mothers remain untested for HIV before the age of 8 weeks.
With Alere™ q HIV-1/2 Detect we can now test at the point of care with accurate molecular results in under an hour. This allows clinicians to start infants on antiretroviral therapy well within recommended guidelines.
More Videos
-
Field Support Staff (FSS) with the Ugandan Ministry of Health
Maximizing patient outcomes of point of care CD4 testing
-
Mobile HIV Testing in Cameroon
Reducing loss to follow up
-
Alere™ q in Action – Early Infant Diagnosis
Hear from KOLs and their experiences
-
Alere™ Connectivity
for the Alere Pima™ CD4
-
Reaching Further in Bhutan
-
The Alere Pima™ CD4 in Bali
Same day CD4 with the Alere Pima™ CD4.
-
Quality Counts with the Alere Determine™ HIV-1/2
Take a look inside Alere Medical Japan.
-
What is the impact of POC testing on HIV health economics?
Point-of-care diagnostics & the HIV treatment cascade.
-
Alere Pima™ CD4 in Zimbabwe
Reaching further with point-of-care CD4 count.
-
Point-of-care CD4 testing – let’s get on with it!
Rapid CD4 testing at the point-of-care is critical to good HIV care
-
The Alere Pima™ CD4
Reaching Further.
-
Inside Alere Technologies
Transformational HIV management platforms.
-
Better access, Better results
Making portable point-of-care CD4 testing easier to reach.
-
The Tutu Tester Mobile Clinic
Positive patient outcomes.
-
Alere Pima™ CD4 Product Detail Pt.1
What is the Alere Pima™ CD4?
-
Alere Pima™ CD4 Product Detail Pt.2
Running an Alere Pima™ CD4 Test
-
Alere Pima™ CD4 Product Detail Pt.3
Connectivity features of the Alere Pima™ CD4
